Literature DB >> 18480575

Clinical and radiological features of Pneumocystis pneumonia in patients with rheumatoid arthritis, in comparison with methotrexate pneumonitis and Pneumocystis pneumonia in acquired immunodeficiency syndrome: a multicenter study.

Hitoshi Tokuda1, Fumikazu Sakai, Hidehiro Yamada, Takeshi Johkoh, Akifumi Imamura, Makoto Dohi, Michito Hirakata, Takashi Yamada, Naoyuki Kamatani, Yoshimi Kikuchi, Shoji Sugii, Tsutomu Takeuchi, Kazuhiro Tateda, Hajime Goto.   

Abstract

OBJECTIVE: To elucidate the clinical and radiological features of Pneumocystis pneumonia (PCP) in patients with rheumatoid arthritis (RA), compared with methotrexate (MTX) pneumonitis in RA and Pneumocystis pneumonia in acquired immunodeficiency syndrome (AIDS). SUBJECTS AND METHODS: Retrospective analysis of 14 PCP cases in RA (RA-PCP), 10 MTX pneumonitis cases in RA (MTX-P) and 11 PCP cases in AIDS (AIDS-PCP) from 9 centers in the Kanto area in the last 6 years.
RESULTS: Compared with AIDS-PCP, both RA-PCP and MTX-P developed more rapidly, showing higher serum CRP and lower plasma beta-D-glucan levels, and more severe oxygenation impairment. In most of the RA-PCP cases, a high dose of corticosteroid was administered as adjunctive therapy, resulting in a favorable outcome. The mortality was 14% in RA-PCP, 0% in AIDS-PCP and 0% in MTX-P cases. In RA-PCP patients the CD4 cell count showed only mild suppression, not reaching the predisposing level for PCP in HIV infection, suggesting that there are risk factors for RA-PCP other than immunosuppression. Radiologic analysis revealed some characteristic patterns of each disease. In MTX-P, diffuse homogeneous ground glass opacity (GGO) with sharp demarcation by interlobular septa (type A GGO) was found in 70%, while in AIDS-PCP diffuse, homogeneous or nonhomogeneous GGO without interlobular septal boundaries (type B GGO) was predominant (91%). In RA-PCP, type A GGO was found in 6 cases and type B GGO in 5 cases, showing the complex nature of this disease.
CONCLUSION: RA-PCP differed considerably from AIDS-PCP clinically and radiologically. Clinically it occurred without severe immunosuppression, and showed characteristic aspects, with more intense inflammation and less parasite burden. Radiologically it mimicked MTX-P in some cases sharing the conspicuous CT features of MTX-P, rendering the distinction of these two disorders difficult.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18480575     DOI: 10.2169/internalmedicine.47.0702

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  22 in total

Review 1.  The Japanese experience with biologic therapies for rheumatoid arthritis.

Authors:  Tsutomu Takeuchi; Hideto Kameda
Journal:  Nat Rev Rheumatol       Date:  2010-09-28       Impact factor: 20.543

2.  Pulmonary function test: its correlation with pulmonary high-resolution computed tomography in patients with rheumatoid arthritis.

Authors:  Daza Leonel; Cervantes Lucia; Muñiz A; Hernández Martha-Alicia; Murillo Blanca
Journal:  Rheumatol Int       Date:  2011-04-17       Impact factor: 2.631

3.  Correlation between imaging features of Pneumocystis Jiroveci Pneumonitis (PCP), CD(4) (+) T lymphocyte count, and plasma HIV viral load: A study in 50 consecutive AIDS patients.

Authors:  Pu-Xuan Lu; Ying-Ying Deng; Shui-Teng Liu; Yan Liu; Ying-Xia Liu; Yi-Xiang J Wang; Wen-Ke Zhu; Xiao-Hua Le; Wei-Ye Yu; Bo-Ping Zhou
Journal:  Quant Imaging Med Surg       Date:  2012-06

Review 4.  Drug-induced interstitial lung disease in molecular targeted therapies: high-resolution CT findings.

Authors:  Fumikazu Sakai; Takeshi Johkoh; Masahiko Kusumoto; Hiroaki Arakawa; Masahiro Takahashi
Journal:  Int J Clin Oncol       Date:  2012-11-10       Impact factor: 3.402

Review 5.  Pneumocystis jirovecii pneumonia in patients receiving tumor-necrosis-factor-inhibitor therapy: implications for chemoprophylaxis.

Authors:  James A Grubbs; John W Baddley
Journal:  Curr Rheumatol Rep       Date:  2014-10       Impact factor: 4.592

6.  Differences in clinical Pneumocystis pneumonia in rheumatoid arthritis and other connective tissue diseases suggesting a rheumatoid-specific interstitial lung injury spectrum.

Authors:  Kota Shimada; Kyoko Yokosuka; Takahiro Nunokawa; Shoji Sugii
Journal:  Clin Rheumatol       Date:  2018-06-06       Impact factor: 2.980

7.  Diagnosis of pneumocystis pneumonia using serum (1-3)-β-D-Glucan: a bivariate meta-analysis and systematic review.

Authors:  Wei-Jie Li; Ya-Ling Guo; Tang-Juan Liu; Ke Wang; Jin-Liang Kong
Journal:  J Thorac Dis       Date:  2015-12       Impact factor: 2.895

Review 8.  Fungal Infections and New Biologic Therapies.

Authors:  Snigdha Vallabhaneni; Tom M Chiller
Journal:  Curr Rheumatol Rep       Date:  2016-05       Impact factor: 4.592

9.  A Four-Center Retrospective Study of the Efficacy and Toxicity of Low-Dose Trimethoprim-Sulfamethoxazole for the Treatment of Pneumocystis Pneumonia in Patients without HIV Infection.

Authors:  Makoto Kosaka; Atsuhito Ushiki; Yuichi Ikuyama; Kazuya Hirai; Akemi Matsuo; Tsutomu Hachiya; Masayuki Hanaoka
Journal:  Antimicrob Agents Chemother       Date:  2017-11-22       Impact factor: 5.191

Review 10.  [Pneumocystis jirovecii pneumonia in patients with autoimmune diseases].

Authors:  S Blaas
Journal:  Z Rheumatol       Date:  2017-11       Impact factor: 1.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.